<table>
<thead>
<tr>
<th>LIST OF CONTENTS</th>
<th>Page No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>INTRODUCTION</td>
<td>1-8</td>
</tr>
<tr>
<td>REVIEW OF LITERATURE</td>
<td>9-62</td>
</tr>
<tr>
<td>Chemotherapy of Malaria</td>
<td>10-34</td>
</tr>
<tr>
<td>Quinine and Quinine Analogues</td>
<td>11-12</td>
</tr>
<tr>
<td>4-Aminoquinolines in Chemotherapy of Malaria</td>
<td>12-15</td>
</tr>
<tr>
<td>Sulfonamides and Sulphones in Treatment of Malaria</td>
<td>15-23</td>
</tr>
<tr>
<td>(i) Half lives of sulphonamides and sulphones</td>
<td>16-17</td>
</tr>
<tr>
<td>(ii) Clinical treatment</td>
<td>17-23</td>
</tr>
<tr>
<td>Pyrimethamine in Treatment of Human Malaria</td>
<td>24</td>
</tr>
<tr>
<td>Mefloquine in Treatment of Human Malaria</td>
<td>24-28</td>
</tr>
<tr>
<td>Triple Combination in Treatment of Malaria</td>
<td>32-34</td>
</tr>
<tr>
<td>Chemotherapeutic Studies in Experimental Models</td>
<td>34-39</td>
</tr>
<tr>
<td>4-Aminoquinolines</td>
<td>34-39</td>
</tr>
<tr>
<td>Immune Status after Subcurative/ Curative Treatment</td>
<td>38-39</td>
</tr>
<tr>
<td>Sulphonamides and Sulphones</td>
<td>39-45</td>
</tr>
<tr>
<td>DHFR Inhibitors</td>
<td>45</td>
</tr>
<tr>
<td>Mefloquine</td>
<td>46</td>
</tr>
<tr>
<td>Drug Combinations</td>
<td>46-47</td>
</tr>
</tbody>
</table>
Use of Triple Combination

Drug Resistance Studies in Malaria

Resistance to mepacrine and 4-aminoquinolines

Resistance to sulphonamides and sulphones in human plasmodia

Resistance to hydrofolate reductase inhibitors in human malaria

Resistance to mefloquine in human

Resistance to drug combinations in fields

Drug Resistance Studies in Experimental Models

Resistance to 4-aminoquinolines in experimental models

Resistance to sulphones and sulphonamides in experimental models

Resistance of DHFR inhibitors in experimental models

Resistance to mefloquine in experimental models

Resistance to fansidar and combination of fansidar with mefloquine

MATERIALS AND METHODS

1. Maintenance of Laboratory Infections

   (A) Parasites

      (i) Rodent parasite

      (ii) Monkey parasite

   (B) Host

      (i) Rodent host

      (ii) Monkey host
(C) Preparation of anticoagulant ... 64
(D) Cryopreservation of the parasite ... 64 - 65
(E) Examination of the blood smears ... 65

2. Chemotherapeutic Drugs ... 66 - 68
(A) Drugs ... 66 - 67
(B) Antimalarial new compounds ... 67
(C) Administration of drugs ... 67 - 68
   (i) Aqueous solution ... 67 - 68
   (ii) Oil solution/suspension ... 68

3. Experimental Studies ... 68 - 74
(A) Selection of host ... 68 - 69
(B) Chemotherapeutic Studies .... 69 - 72
   (a) Against rodent parasite P. yoelii \(_{nigeriensis}\) ... 69 - 72
   (i) Testing of long acting nature of antimalarial drugs ... 69
   (ii) Blood schizontocidal activity ... 69 - 70
      [I] Determination of mean survival time ... 70
      [II] Determination of minimum effective dose ... 70
   (iii) Efficacy of single dose treatment ... 70 - 71
   (iv) Efficacy of new compounds in single dose treatment ... 71 - 72
   (b) Against monkey parasite P. knowlesi \(_{W_1}\) ... 72
   (i) Response of antimalarial drugs ... 72
(C) Studies on Drug Resistance

(i) Selection of sulphadoxine/pyrimethamine/mefloquine resistant strain of \( P. \) \( \text{yoelii nigeriensis} \) 72 - 73

(ii) Cross chemotherapeutic studies against ... 73 multiple resistant strain of \( P. \) \( \text{yoelii nigeriensis} \)

(iii) Selection of chloroquine and amodiaquine resistant strain of \( P. \) \( \text{knowlesi} \) 73

(D) Immune Status of Rhesus Monkey After Treatment 74

(i) Challenge after subcurative treatment .. 74 with chloroquine

(ii) Challenge after curative treatment with .. 74 chloroquine

RESULTS

(A) Chemotherapeutic studies

1. Variation in inocula of \( P. \) \( \text{yoelii} \) nigeriensis in Swiss mice host 75
2. Effect of ground nut oil .. 76
3. Testing of long-acting nature .. 76 - 78 of antimalarial drugs
4. Efficacy of single dose treatment ... 78 - 81
5. Challenge and rechallenge of mice .. 81 - 83 after treatment
6. Blood schizontocidal activity of new .. 83 - 84 antimalarial drugs received from University of Lucknow (Chemistry Department)
7. Efficacy of new antimalarial compounds in single dose treatment 84 - 85
8. Chemotherapeutic response of antimalarial .. 85 drugs against normal strain(\( W_1 \)) of \( P. \) \( \text{knowlesi} \)
(B) Drug Resisitance Studies

1. Drug resistance studies against rodent parasite

(a) Selection of sulphadoxine/pyrimethamine/ mefloquine resistant strain of *P. yoelii nigeriensis* ... 86 - 87

(b) Stability of resistance ... 87

(c) Cross chemotherapeutic studies ... 87 - 89

2. Drug resistance studies against monkey parasite

I. Selection of chloroquine resistant strain of *P. knowlesi*

(i) Suppressive (subcurative) chloroquine therapy (i/m) 90 - 100

(A) Ist passage ... 90 - 92

(B) IInd passage ... 92 - 93

(C) IIIrd serial passage ... 93 - 94

(D) Chemotherapy of stabilates ... 94 - 100 *P. knowlesi*

(a) Chemotherapy of stabilates collected in Ist passage ... 94 - 96

(b) Chemotherapy of stabilates collected during IInd passage ... 96 - 97

(c) Chemotherapy of stabilates collected during IIIrd passage ... 97 - 98

(d) Chemotherapy of stabilates of *P. knowlesi* collected from recrudescence of parasite after treatment ... 98 - 100

(ii) Relapse Method ... 100 - 102

(A) Ist passage ... 102
II. Selection of amodiaquine resistant strain of *P. knowlesi*

(a) Subcurative treatment with amodiaquine

(A) Ist passage

(B) IInd passage

(b) Relapse method

(A) Ist passage

(B) IInd passage

C. Studies on Immune Status of Monkeys

(i) Treatment with suppressive doses

(ii) Treatment with curative doses

(iii) Rechallenge of monkeys

DISCUSSION

(A) Selection of host for chemotherapeutic studies with *P. yoelii nigeriensis*

(B) Chemotherapeutic studies with *P. yoelii* nigeriensis

(i) Long-acting antimalarial efficacy antimalarial and sulfa drugs

(ii) Efficacy of new antimalarial compounds in single dose treatment

(iii) Blood schizontocidal activity of new antimalarial drugs received from Chemistry Department of Lucknow University

(C) Chemotherapeutic response of antimalarial drugs against normal strain (*W*) of *P. knowlesi*

(D) Drug resistance studies in malaria
(i) Resistance to sulphadoxine/pyrimethamine/mefloquine combination in rodent model

(ii) Resistance to chloroquine and amodiaquine in *P. knowlesi*

(E) Immune status after curative/subcurative treatment

SUMMARY

BIBLIOGRAPHY